 InPharm | Merck KGaA signs MS and cancer research deal InPharm In August Biogen and Abbott's MS drug daclizumab, a new injectable, performed well in a Phase IIb study, although two deaths marred the overall results. But Novartis' oral drug Gilenya (fingolimod) is now on the market and two other oral MS treatments ... |
